Sanofi Pasteur/Crucell H7N1 Vaccine Trials Begin
A phase I clinical trial is reportedly the first to assess safety and efficacy of a split, inactivated prototype pandemic H7N1 vaccine.
Lyon, France - Sanofi
pasteur, within the framework of the European Commission's
collaborative research project, announced on 19 SEP 2006 that it had
generated the first clinical trial lot of a new generation of H7N1
pandemic vaccine. This research is part of an overall pandemic
preparedness program begun earlier with H5N1 vaccine research. The H7N1
avian influenza virus struck Italian poultry in 1999. The production
uses cell-based technology from Sanofi pasteur partner Crucell
N.V.
While both H5 and H7 subtypes have caused human infections in the
last three years, H5 has received more attention.
from Company Press Release